Gsk Plc ADR (GSK)
$39.39
0.00 (0.00%)
GSK Stock Quote Delayed 30 Minutes
GSK: GlaxoSmithKline Investigating Bribery Allegations in Iraq
GlaxoSmithKline (GSK) is investigating allegations of bribery in Iraq as the company still reels from corruption charges in China.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
212.12B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
2,571
Day's Range
-
52-Week Range
$33.67 - $45.92
Dividend & Yield
$1.44 (3.67%)
GSK Stock Predictions, Articles, and Gsk Plc ADR News
5 Pharma Stocks to Buy for Big Dividends
Drugmakers aren't known for big dividends, but the pharmaceutical industry can actually offer something for income investors.
Has JNJ Finally Moved Past Its Quality-Control Woes?
Johnson & Johnson is throwing off billions of dollars to settle quality-control cases, but has Alex Gorsky ensured the worst is over for JNJ?
These 48 Blue Chips Are On the Move
It's time to review or gradings for 48 Blue Chip stocks in our portfolio
Buy These 3 Stocks for a Monthly Paycheck
Investors with an extra-close eye on regular retirement income can secure themselves a monthly paycheck by bundling trios of dividend stocks.
Biotech Blowout: 3 Stocks Taking a Hit
The risky side of biotech stocks reared its ugly head in the past couple of days, sending three stocks to the mat in the wake of bad news.
Should I Buy GlaxoSmithKline (GSK)? 3 Pros, 3 Cons
GlaxoSmithKline is seeking approval for the world's first malaria vaccine, but high debt and low growth mean investors should think twice before buying.
3 Healthcare Stocks With Healthy Dividends
Protect yourself from the headwinds facing healthcare stocks by snatching up names that offer -- and are likely to keep offering -- big-time dividends.
GlaxoSmithKline to Pay $229M to Settle Diabetes Drug Suit
GlaxoSmithKline announced Wednesday, that it will spend $229 million to settle lawsuits concerning the advertising of its diabetes drug Avandia.
Attention Yield Seekers: Now Is Your Chance to Act!
In this low interest rate environment, dividends are still looking great, and these 26 stocks are about to go ex-dividend. Decide how to play them today
AstraZeneca to Purchase Omthera
AstraZeneca will purchase Omertha, a make of fish-oil based pharmaceuticals as it continues to bolster its cardiovascular product lineup
An HIV ‘Cure’? Let’s Not Overstate the Success
Merck, J&J and others won't be dropping their research to recreate the success seen in the early treatment of an HIV-positive child.
Newborn Cured of HIV
A little girl in Mississippi, who was born infected with HIV, was apparently cured of the disease after receiving a three drug cocktail shortly after birth.
Biotech Movers: Arena Gets Warned, MAP Gets an Offer
Among last week's highlights, Europe raises questions about Arena's obesity drug, Belviq, and Allergan offers $958 million for MAP Pharmaceuticals.
3 Pharmaceutical Stocks to Sell Now
The ratings of three Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Flu’s Pain Is All Gain for These Companies
As this year's flu season intensifies, so do the profits for some businesses such as vaccine makers, pharmacies and even certain food and beverage makers.
Flu Season: Where Investors Can Find Relief
This year's flu looks particularly troublesome, but that's good new for the many companies that benefit from flu sufferers' ills. Here's a look at some of them.
9 Pharmaceutical Stocks to Sell Now
This week, the overall grades of nine Pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Big Pharma: 2012-13’s Flu Vaccine Field
Here's a look at the various big pharma stocks that could see a bump from an early start to this year's flu season.
Pharma Stock Breaking Down — Get Out Now
GlaxoSmithKline suffered a major reversal and is flashing a sell signal. Get out now.
Biotech Movers: Regeneron Pops, 3 Flop
While Regeneron soared on behind its macular degeneration treatment, Dynavax, Navidea and AspenBio suffered serious setbacks.
